Lilly adds $1.8 billion to its Irish manufacturing sites

Eli Lilly announced on September 12, 2024, that it will invest $1.8 billion more in its manufacturing sites in Limerick and Kinsale, Ireland, to expand production capacity for active ingredients used in its diabetes, obesity and Alzheimer's medicines ^[1][2].

The money splits two ways. Limerick, a site still under construction, gets an added $1 billion, bringing Lilly's total investment there to $2 billion ^[1][2]. That facility will produce biologic active ingredients, including for Kisunla, Lilly's recently approved Alzheimer's treatment, and other biologic medicines ^[1][2]. Production at Limerick is expected to start in 2026, and the expansion will add 150 jobs, bringing total employment there to 450 ^[1][2]. The project still needs planning approval from the Limerick City and County Council ^[1].

Kinsale, about two hours south, gets a newly disclosed $800 million expansion that has already been completed ^[1][2]. This site began making Mounjaro and Zepbound, Lilly's tirzepatide products for diabetes and obesity, last year ^[2]. The Kinsale facility uses a digital-first, continuous manufacturing process to produce complex peptides, and it recently won the Innovation category at the International Society of Pharmaceutical Engineers' Facility of the Year awards ^[1][2].

This Irish spending is part of a much larger buildout. Since 2020, Lilly has committed more than $20 billion to build, expand, or acquire manufacturing sites in the U.S. and Europe ^[1][2]. Other pieces of that plan include an additional $5.3 billion for a manufacturing complex in Lebanon, Indiana, announced four months earlier, bringing total spending on that 600-acre campus to $9 billion; a $2.5 billion plant under construction in Alzey, Germany, expected to start production in 2027; and a site in the Research Triangle Park area of North Carolina projected to become fully operational in 2027 ^[2].

Why it matters for patients

Demand for tirzepatide products Mounjaro and Zepbound has outpaced Lilly's ability to make them, contributing to periodic shortages that have frustrated patients trying to fill prescriptions ^[2]. More manufacturing capacity, once it comes online, is aimed at easing that supply squeeze over time, though the Limerick expansion will not begin producing active ingredients until 2026 at the earliest ^[1][2], and the announcement itself is a forward-looking statement subject to risks in drug manufacturing, development, and commercialization ^[1].

The Kinsale expansion is already complete and was already making Mounjaro and Zepbound before this announcement, so it may have a more immediate effect on the supply chain than the Limerick site ^[1][2]. Patients should note that none of this changes prices, insurance coverage, or availability in the immediate term; it reflects a manufacturer's long-term bet on continued demand for its GLP-1 and biologic products ^[1][2].

Lilly executive Edgardo Hernandez said the investments are meant to help "millions of people with diabetes, obesity and Alzheimer's disease live the healthiest lives possible" and that the facilities will also support future pipeline molecules ^[1][2].

What happens next

Lilly expects to submit a planning application for the Limerick expansion to local authorities, with biologic active ingredient production targeted to start in 2026 ^[1][2]. The company's Alzey, Germany plant is expected to begin production in 2027, as is its North Carolina site ^[2]. Lilly is competing with Novo Nordisk, maker of Ozempic and Wegovy, in the fast-growing GLP-1 market, and further manufacturing announcements from either company are possible as demand continues ^[2].